Although monotherapy with PARP inhibitors is not satisfactorily efficacious for GBM cells with wild‐type BRCA1/2 [16, 17], DNA‐damaging agents such as temozolomide (TMZ) and radiation increase GBM sensitivity to the PARP inhibitor olaparib [18, 19]. The gene discussed is BRCA1; the disease is glioblastoma.